There are multiple drug names and mechanisms, ongoing debates about who should take the drugs, questions about cost and access, and anxiety about what happens if you stop taking them
The clinical investigators specifically noted that "gastrointestinal adverse events were partially mitigated by the use of a lower starting dose." Starting at 1 mg, which is what the Phase 3 TRIUMPH trials use, provides even more tolerability protection
In diabetic kidney disease patients, a reduction in insulin levels, albuminuria, and the progression of renal failure were observed as a GLP-1R effect [56, 57]
Changes in lean body mass with glucagon-like peptide1based therapies and mitigation strategies
This combination helps control cravings and prolong satiety
To finish, I wanted to share some positive stories from people who have used these weight loss drugs in our groups